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Mutation analysis of CBP and PCAF reveals rare inactivating
mutations in cancer cell lines but not in primary tumours
H O¨zdag˘1, SJ Batley1, A Fo¨rsti1,4, NG Iyer1, Y Daigo1, J Boutell2, MJ Arends3, BAJ Ponder1, T Kouzarides2 and
C Caldas*,1
1Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge CB2 2XZ, UK; 2Wellcome/CRC
Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, UK; 3Molecular Histopathology, University of
Cambridge Pathology Department, Addenbrooke’s Hospital, Box 235, Level 3, Hills Road, Cambridge CB2 2QQ, UK
In this study we screened the histone acetyltransferases CBP and PCAF for mutations in human epithelial cancer cell lines and
primary tumours. We identified two CBP truncations (both in cell lines), seven PCAF missense variants and four CBP intronic
microdeletions. These data suggest that neither gene is commonly inactivated in human epithelial cancers.
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The addition of an acetyl group to specific lysine residues within
the N-terminal region of the four core histone proteins by acetyl-
transferases, causes the destabilisation of the chromatin structure
and enhances access of transcription factors and other DNA-bind-
ing components to DNA (Grunstein, 1997). The histone
acetyltransferases CBP, P300 and PCAF also acetylate sequence-
specific transcription factors such as P53. CBP was originally
isolated on the basis of its interaction with CREB in response to
cAMP signalling (Chrivia et al, 1993). P300 was purified as a cellu-
lar protein, which binds the adenoviral protein E1A (Eckner et al,
1994). PCAF, P300/CBP-associated factor, was the first mammalian
histone acetyltransferase discovered on the basis of homology to
yeast Gcn5p (Yang et al, 1996). The fact that histone acetyltrans-
ferases are involved in cell proliferation and differentiation
suggests that they may be involved in cancer. Indeed P300 (also
known as EP300) and CBP are fused to MLL in acute myeloid
leukaemia. It is also known that P300, CBP and PCAF are targeted
by viral oncoprotein E1A (Eckner et al, 1994; Yang et al, 1996;
Chakravarti et al, 1999). In colorectal and gastric carcinomas two
somatic P300 missense mutations coupled to deletion of the second
allele of the gene were identified (Muruoka et al, 1996). The role of
P300 as a tumour suppressor gene was later confirmed with the
identification of truncating, insertion and missense mutations in
primary tumours and cancer cell lines, associated with inactivation
of the second allele (Gayther et al, 2000). In this study we screened
the whole coding sequence and intron – exon boundaries of both
CBP and PCAF for somatic mutations in a series of human
primary tumours and cancer cell lines. We also screened a panel
of cell lines for truncating P300 mutations using Western blotting.
MATERIALS AND METHODS
Samples
The CBP gene was screened in 179 DNA samples isolated from 59
primary breast tumours, 37 primary ovarian tumours, 20 colorectal
tumours, and 63 cancer cell lines. The PCAF gene was screened in
80 cancer cell lines (31 breast, 25 ovarian, 10 pancreatic, 6 SCLC, 5
colorectal, 1 NSCLC, 1 MISC, 1 BCLL) and 20 primary colorectal
tumours. In all cases the collection of tumour material was done
with Local Research Ethics Committee approval. All tumours were
‘flash’ frozen immediately following surgery. Cell lines were
obtained from ATCC and ECACC cell repository or as a gift from
collaborating laboratories.
Preparation of DNA and RNA
Frozen primary tumours were serially sectioned onto slides.
Tumour tissue was microdissected and DNA extracted by SDS-
proteinase K digestion followed by phenol-chloroform extraction.
Germ-line DNA was prepared from either a matching blood
sample or from normal tissue. Cell line DNA was extracted by
either proteinase K or DNAzolTM (Gibco BRL). RNA was extracted
with TriZolTM (Gibco BRL). cDNA was synthesized by reverse
transcription of RNA using random hexamers and Superscript II
(Gibco BRL).
Determination of the exon – intron structure of CBP and
PCAF
The exon-intron structure of CBP and PCAF were determined
from the available cDNA and genomic DNA sequences in
Genbank (NCBI). CBP is a 8694 bp cDNA consisting of 32 exons
distributed over 154 Kb of genomic sequence at chromosome
band 16p13.3. PCAF is a 2957 bp cDNA consisting of 20 exons
spread over 114 Kb of genomic sequence at chromosome band
3p24.
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Polymerase chain reaction
CBP was amplified from gDNA in 43 fragments and PCAF was
amplified from cDNA in 13 fragments of approximately 200 –
400 bp (oligonucleotide primer sequences are available on
request, ho212@cam.ac.uk). PCAF sequence alterations were
confirmed subsequently in genomic DNA. Amplification reactions
(30 ml) contained 20 mM (NH4)2SO4, 75 mM TrisHCl, pH 9.0 at
258C, 0.1% (w v71) Tween, 2.5 – 3 mM MgCl2, 200 mM dNTP,
10 pmoles of each primer and 2.5 U of Red Hot DNA polymer-
ase (Advanced Biotechnologies). The amplifications were done
using a DNA Engine Tetrad, MJ Research PTC-225 Peltier Ther-
mal Cycler.
Protein truncation test
PCAF coding sequence was analysed initially by PTT. Cell lines
HCT15 and OVCAR8, which showed an altered sized P300 protein
on Western blot were also analysed by PTT. RT – PCR amplifica-
tion was done in overlapping fragments of approximately 1000 –
1200 bp in length each, using a 5’ oligo containing the appropriate
sequences (oligonucleotide sequences are available on request).
PTT reactions were performed following the manufacturer’s proto-
col (Promega). Alterations found in PTT were confirmed by
sequencing.
SSCP/HA (Single Strand Conformation Polymorphism/
Heteroduplex Analysis)
Formamide loading buffer was added to PCR products. The mix
was denatured at 958C for 10 min and kept on ice until loading
onto 0.86MDE (Mutation Detection Enhancement) gel (Flowgen),
both with and/or without 10% Glycerol. Gels were run overnight at
120 V and 48C.
Western blot analysis
Western blot analysis was used to screen for P300 truncating muta-
tions in a panel of 24 cell lines. We also performed Western blot in
cell lines identified to have truncating CBP mutations. Cell extracts
were prepared by direct lysis on cell culture plates (TBS, 0.5% NP-
40, 5 mM EDTA, Complete Protease Inhibitor Coctail, Boehringer),
then electrophoresed in pre-cast polyacrylamide Tris-Glycine gels
(Novex). The separated proteins were transferred to nitrocellulose
membrane (Millipore) and hybridised with the respective primary
(CBP A-22 Santa Cruz, P300 N-15 Santa Cruz) and secondary anti-
bodies (Dako). Detection employed the ECL kit (Amersham).
DNA Sequencing
Purified PCR products were sequenced using ABI PrismR BigDye
terminators and an ABI377 sequencer or ABI3100 genetic analyzer
(Applied Biosystems, Foster, CA, USA). All samples with a muta-
tion were re-amplified and re-sequenced.
RESULTS AND DISCUSSION
CBP mutations
Two different CBP truncating mutations were identified in the 63
cell lines analysed (Table 1). Shin3, an ovarian cancer cell line, was
found to have a heterozygous 22 bp deletion in intron 21 at posi-
tion 74 (Figure 1A). This intronic deletion was shown to cause an
in-frame deletion of the whole exon 22 at the cDNA level (Figure
1B). In four cancer cell lines (LK1, LK2, PA1, CH1) an identical
heterozygous insertion of an A was found in intron 31 at position
77 (Figure 1C). This insertion was shown to create an alternative
splice donor site. This in turn caused a frame-shift and a prema-
ture stop codon at nucleotide 5457 (codon 1795). This
heterozygous mutation was confirmed using Western blotting
(Figure 1D). The finding of the identical mutation raised the suspi-
cion of cross contamination between cell lines. HLA typing was
performed and the results showed that these cell lines were indeed
the same, despite originating from two different labs (data not
shown). We considered these as a single cell line for purposes of
mutation frequency analysis and therefore the truncating mutations
were identified in two distinct cell lines out of 60 analysed (3%).
No truncating mutations were identified in 116 primary tumours.
Small intronic microdeletions in CBP were identified in four
samples (Table 2). A primary colorectal cancer had a heterozygous
deletion of T at position 72 in intron 18. This tumour had no
molecular phenotype suggestive of microsatellite instability (MSI).
Two cancer cell lines with MSI, OVIP and HCT15, had an identical
microdeletion. These intronic microdeletions, which were very
close to the splice donor site, had no apparent effect on mRNA
splicing as tested by amplification of cDNA with primers flanking
exon19. A breast cancer cell line, MT3, was found to have a dele-
tion of T in intron 14 at position 782, with no apparent effect on
splicing as tested by RT – PCR. This cell line is also MSI+. Uncom-
mon CBP single nucleotide polymorphisms were also detected
(Table 3).
Although we have characterised two truncating CBP mutations
in cancer cell lines, the absence of inactivating mutations in the
primary tumours analysed prevents us from unequivocally estab-
lishing the role of CBP in human primary cancers. Nevertheless
the uncommon mutations identified, together with the increased
tumour incidence in Rubinstein-Taybi syndrome (Petrij et al,
1995) and the tumorigenic phenotype in CBP mice (Kung et al,
2000) provide circumstantial evidence for a possible role of CBP
as a tumour suppressor gene. We can only speculate on the signif-
icance of the intronic microdeletions seen, but we note that we
have previously identified similar intronic microdeletions in other
genes in MSI cell lines and primary tumours (data not shown).
Missense PCAF sequence alterations
No truncating mutations were identified in the PCAF gene. We
used cDNA to screen for truncating mutations and therefore
nonsense mediated RNA decay (Maquat, 1995) could have contrib-
uted to a lower sensitivity of the mutation screen. Missense
sequence alterations in PCAF were identified in 1 out of 20
primary tumours (5%) and 5 out of 80 cell lines (6%). In a color-
ectal cancer case the missense variant was a C to A transversion at
nucleotide 2595 in exon 17, resulting in a proline to threonine
substitution at codon 713. The same sequence alteration was also
found in the germ-line DNA of the same individual (Table 2).
The functional significance of this single nucleotide polymorphism
was not tested but this residue is conserved in mouse and human
GCN5, suggesting it might be important for protein function.
Sequence analysis in DNA extracted from laser capture microdis-
sected normal and tumour tissue samples confirmed the
heterozygous mutation in both tumour and germ-line DNA, and
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Table 1 Truncating mutations in CBP and P300
Gene Sample Sequence alteration Result
CBP Shin3 IVS21-4del22 In frame deletion of exon 22
CBP LK1 IVS31-7InsA Stop1795
LK2
PA1
CH1
P300 HCT15 4239G4T E1014X
P300 OVCAR8 6387DelT S1733X
Mutations of CBP, PCAF and P300 in epithelial cancers
H O¨zdag˘ et al
1163
ª 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1162 – 1165
therefore the mutation is not associated with somatic allelic dele-
tion. A missense alteration at nucleotide 1615 (N386S) was
found in four cell lines (Ovmana, Hela, L23, MC4000/ Matu).
The mouse homologue of this residue is serine, implying that this
alteration is a polymorphism. An ovarian cancer cell line, OVI-P,
had a C to T transition at nucleotide 2415 resulting in Arg653Trp
substitution. This arginine residue is conserved in human GCN5,
and therefore this substitution could impair protein function. In
addition to these missense sequence alterations a single nucleotide
deletion in the 3’ untranslated region of PCAF was found in a
colon cancer cell line, SW48. Three silent PCAF polymorphisms
were also identified (Table 3).
The missense sequence alteration at nucleotide 1615 has been
previously reported and considered a polymorphism (Nishimori
et al, 2000).
Truncating P300 mutations
We have previously shown that truncating mutations resulted in
the production of stable protein, detectable by Western blot. Using
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Figure 1 Truncating mutations in CBP and P300. (A) Sequencing chromatogram of Shin3 gDNA showing CBP IVS21-4del22 causing in frame deletion of
exon 22. (B) Sequencing chromatogram of Shin3 cDNA showing in frame deletion of CBP exon 22. (C) Sequencing chromatogram of CH1 showing CBP
IVS31-7InsA (Stop 1795). (D) Western blot analysis of CBP in CH1 showing truncated protein (Arrow). (E) Sequencing chromatogram of Ovcar8 (reverse
strand) showing P300 6387delT (Stop1733). (F) Sequencing chromatogram of HCT15 showing P300 4239 G4T (Stop1014).
Table 2 Intronic microdeletions in CBP and missense sequence altera-
tions in PCAF
Gene Frequency (%) Sequence alteration Result
CBP 0.5 IVS14-82delT –
CBP 2 IVS18-2DelT –
PCAF 5 1615A4G N386S
PCAF 1 2415C4T R653W
PCAF 1 2595C4A P713T
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this approach we studied a panel of 24 cell lines and in two (8.3%)
truncated protein was detected (Table 1). OVCAR8 had two bands
on the Western blot, one of normal size and one from a truncated
protein, suggesting a heterozygous mutation. Sequencing confirmed
a heterozygous frameshift deletion (6387delT) resulting in trunca-
tion of the protein at codon 1733 (Figure 1E). HCT15 expressed
only a truncated protein and sequencing showed a homozygous
transversion, 4239 G?T, generating a stop codon (Figure 1F). This
same mutation was previously found in DLD1 as a heterozygous
alteration. Since it is known that DLD1 and HCT15 were derived
from the same patient (Chen et al, 1995), one can interpret this
result as indicating that the two cell lines were derived from differ-
ent areas of the cancer or that the genetic progression represents an
event occuring during in vitro culture.
The finding of truncating P300 mutations was not a surprise,
since we have previously shown that P300 mutations occur in a
small percentage of human epithelial malignancies and others have
also identified truncating mutations (Oshima et al, 2001). We have
now analysed a total of 222 cancer samples and truncating muta-
tions have been detected in 6 out of 107 (5.6%) cell lines and 2
out of 115 (1.7%) primary tumours.
In conclusion, this report revealed inactivating CBP mutations
in cancer cell lines but not in primary tumours. It also identified
a few missense alterations in PCAF and intronic sequence variants
in CBP. These data are insufficient to establish a role for either
gene in epithelial cancers.
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Table 3 Silent polymorphisms in CBP and PCAF
Gene Frequency (%) Sequence alteration
CBP 0.5 1263G4A
CBP 0.5 1311G4A
CBP 0.5 1849C4A
CBP 0.5 2151T4C
CBP 0.5 IVS12-37C4T (Homozygous)
CBP 0.5 IVS12-18G4A
CBP 1.6 4099C4A
CBP 2.7 IVS21-8G4A
CBP 1.1 IVS24+6G4A
CBP 1.6 IVS28-13G?C
CBP 1.1 IVS29+117A4T (Homozygous)
PCAF 2 767G4A
PCAF 3% 1037C4T
PCAF 3% 1721T4C
Mutations of CBP, PCAF and P300 in epithelial cancers
H O¨zdag˘ et al
1165
ª 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1162 – 1165
